Skip to Main Content

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)

Conditions

Diseases of the Digestive System - Liver | Diseases of the Digestive System - Pancreas | Diseases of the Digestive System - Small Intestines, Large Intestines & Rectum

Phase III

What is the purpose of this trial?

The main objective of the study is to evaluate the effect of daily oral administration of 80mg elafibranor on cholestasis (impairment of bile formation and/or bile accumulation) in patients with PBC and inadequate response or intolerance to Ursodeoxycholic Acid (UCDA).

  • Trial with
    Genfit
  • Start Date
    12/03/2021
  • End Date
    09/30/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    12/17/2021
  • Study HIC
    #2000030228